JP2020520677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520677A5 JP2020520677A5 JP2020515296A JP2020515296A JP2020520677A5 JP 2020520677 A5 JP2020520677 A5 JP 2020520677A5 JP 2020515296 A JP2020515296 A JP 2020515296A JP 2020515296 A JP2020515296 A JP 2020515296A JP 2020520677 A5 JP2020520677 A5 JP 2020520677A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- ammonia
- hyperammonemia
- glutamine synthetase
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 72
- 239000003795 chemical substances by application Substances 0.000 claims 38
- 229910021529 ammonia Inorganic materials 0.000 claims 36
- 108091006065 Gs proteins Proteins 0.000 claims 27
- 206010020575 Hyperammonaemia Diseases 0.000 claims 27
- 102000005396 glutamine synthetase Human genes 0.000 claims 27
- 108020002326 glutamine synthetase Proteins 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 20
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000002265 prevention Effects 0.000 claims 19
- 239000013604 expression vector Substances 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 11
- 239000002202 Polyethylene glycol Substances 0.000 claims 10
- 229920001223 polyethylene glycol Polymers 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 239000002516 radical scavenger Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 238000007911 parenteral administration Methods 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 230000009885 systemic effect Effects 0.000 claims 6
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000004143 urea cycle Effects 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 3
- 239000006096 absorbing agent Substances 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960003424 phenylacetic acid Drugs 0.000 claims 2
- 239000003279 phenylacetic acid Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- GVNOKKGCPWLUOT-UHFFFAOYSA-N 2-phenylbutanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCC(C(O)=O)C1=CC=CC=C1 GVNOKKGCPWLUOT-UHFFFAOYSA-N 0.000 claims 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000027219 Deficiency disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- ITIONVBQFUNVJV-UHFFFAOYSA-N Etomidoline Chemical compound C12=CC=CC=C2C(=O)N(CC)C1NC(C=C1)=CC=C1OCCN1CCCCC1 ITIONVBQFUNVJV-UHFFFAOYSA-N 0.000 claims 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003456 ion exchange resin Substances 0.000 claims 1
- 229920003303 ion-exchange polymer Polymers 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 1
- 229960003040 rifaximin Drugs 0.000 claims 1
- 229940006198 sodium phenylacetate Drugs 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023038030A JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1708288.4A GB201708288D0 (en) | 2017-05-24 | 2017-05-24 | Use of glutamine synthetase for treating hyperammonemia |
| GB1708288.4 | 2017-05-24 | ||
| GB1800867.2 | 2018-01-19 | ||
| GBGB1800867.2A GB201800867D0 (en) | 2018-01-19 | 2018-01-19 | Use of glutamine synthetase for treating hyperammonemia |
| PCT/GB2018/051415 WO2018215780A1 (en) | 2017-05-24 | 2018-05-24 | Use of glutamine synthetase for treating hyperammonemia |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038030A Division JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A Division JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520677A JP2020520677A (ja) | 2020-07-16 |
| JP2020520677A5 true JP2020520677A5 (enExample) | 2021-07-26 |
Family
ID=62492675
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515296A Pending JP2020520677A (ja) | 2017-05-24 | 2018-05-24 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2023038030A Active JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A Pending JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023038030A Active JP7688926B2 (ja) | 2017-05-24 | 2023-03-10 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
| JP2024026784A Pending JP2024059833A (ja) | 2017-05-24 | 2024-02-26 | 高アンモニア血症を治療するためのグルタミン合成酵素の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US12359184B2 (enExample) |
| EP (3) | EP4119133A1 (enExample) |
| JP (3) | JP2020520677A (enExample) |
| KR (2) | KR20200018488A (enExample) |
| CN (2) | CN111093641A (enExample) |
| AU (2) | AU2018272294B2 (enExample) |
| BR (1) | BR112019024750A2 (enExample) |
| CA (1) | CA3064352A1 (enExample) |
| IL (1) | IL270817B2 (enExample) |
| MX (2) | MX2019014027A (enExample) |
| WO (1) | WO2018215780A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200018488A (ko) * | 2017-05-24 | 2020-02-19 | 토리스 게엠베하 | 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도 |
| EP3856231A1 (en) * | 2018-09-28 | 2021-08-04 | Thoeris GmbH | Use of glutamine synthetase for treating fatty liver disease |
| CN110133287B (zh) * | 2019-05-22 | 2021-07-30 | 上海碧云天生物技术有限公司 | 蛋白抽提溶液及其应用 |
| KR102686466B1 (ko) | 2020-06-30 | 2024-07-18 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물 |
| JP7865272B2 (ja) | 2023-05-24 | 2026-05-26 | トヨタ自動車株式会社 | 二次電池 |
| CN118949035A (zh) * | 2024-07-31 | 2024-11-15 | 北京大学第一医院(北京大学第一临床医学院) | Glul生物标志物在心力衰竭诊断、治疗或预后预测中的应用 |
| CN122075711A (zh) * | 2026-04-24 | 2026-05-26 | 上海健康医学院 | 组蛋白去乙酰化酶抑制剂HDACi在制备预防和/或治疗高血氨诱发脑病的药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7590493B2 (en) | 2000-07-31 | 2009-09-15 | Ocimum Biosolutions, Inc. | Methods for determining hepatotoxins |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US6451547B1 (en) | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AUPR805101A0 (en) | 2001-10-03 | 2001-10-25 | University Of New South Wales, The | A method of genetic screening using an amplifiable gene |
| JP2003225093A (ja) | 2001-11-30 | 2003-08-12 | Sumitomo Pharmaceut Co Ltd | 軟骨障害マーカー及びその利用 |
| US6875792B2 (en) | 2002-01-31 | 2005-04-05 | Mso Pharma Llc | Dosage form of L-Methionine S-Sulfoximine |
| JP2003274963A (ja) | 2002-03-22 | 2003-09-30 | Japan Science & Technology Corp | 遺伝子組換え細胞株及びそれを用いた肝機能補助装置 |
| US20050074865A1 (en) * | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| AU2003303144A1 (en) | 2002-10-18 | 2004-07-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050255114A1 (en) | 2003-04-07 | 2005-11-17 | Nuvelo, Inc. | Methods and diagnosis for the treatment of preeclampsia |
| WO2004106489A2 (en) | 2003-05-21 | 2004-12-09 | Divergence, Inc | Nematode GS-like sequences |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20070098702A1 (en) * | 2005-02-17 | 2007-05-03 | University Of Maryland, Baltimore | Recombinant protein polymer vectors for systemic gene delivery |
| EP1752143A1 (en) | 2005-08-08 | 2007-02-14 | NewThera | Novel uses for drugs targeting glutamine synthetase |
| CA2634510C (en) | 2005-12-21 | 2018-01-09 | Universite Catholique De Louvain | Isolated liver stem cells |
| RU2362572C2 (ru) | 2007-07-17 | 2009-07-27 | Юрий Георгиевич Каминский | Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы |
| WO2009134460A1 (en) * | 2008-04-29 | 2009-11-05 | Hyperion Therapeutics | Methods of treatment using ammonia-scavenging drugs |
| US9273296B2 (en) | 2008-09-08 | 2016-03-01 | Cellectis | Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof |
| WO2011147981A2 (en) | 2010-05-28 | 2011-12-01 | Mind-Nrg Sa | Neuregulin isoforms, neuregulin polypeptides and uses thereof |
| WO2013020914A1 (en) * | 2011-08-10 | 2013-02-14 | Celares Gmbh | Peg-conjugated peptides |
| KR101494072B1 (ko) | 2012-03-12 | 2015-02-17 | 한화케미칼 주식회사 | 변이된 글루타민 합성효소 유전자를 포함하는 벡터 및 이를 이용한 목적 단백질의 생산방법 |
| EP2674495A1 (en) | 2012-06-14 | 2013-12-18 | Sanofi | CHO expression system |
| MX377806B (es) | 2014-11-07 | 2025-03-11 | Instituto Nac De Ciencias Medicas Y Nutricion Salvador Zubiran | Uso de un baculovirus recombinante que media la expresión de la glutamina sintetasa para tratar la encefalopatía hepática. |
| KR20230018526A (ko) * | 2014-11-24 | 2023-02-07 | 유씨엘 비즈니스 리미티드 | 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료 |
| AU2016274311A1 (en) * | 2015-06-10 | 2018-01-18 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| WO2017173043A1 (en) | 2016-03-30 | 2017-10-05 | Spark Therapeutics, Inc. | Cell line for recombinant protein and/or viral vector production |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| JP6972022B2 (ja) | 2016-05-11 | 2021-11-24 | アムジエン・インコーポレーテツド | グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択 |
| CN110023500B (zh) | 2016-11-16 | 2024-10-11 | 新加坡科技研究局 | 作为选择标记的减毒谷氨酰胺合成酶 |
| KR20200018488A (ko) | 2017-05-24 | 2020-02-19 | 토리스 게엠베하 | 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도 |
| US11479792B2 (en) | 2017-07-13 | 2022-10-25 | Upside Foods, Inc. | Compositions and methods for increasing the efficiency of cell cultures used for food production |
| WO2019028273A1 (en) | 2017-08-02 | 2019-02-07 | Dna2.0, Inc. Dba Atum | DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS |
| CN109988777A (zh) | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
| CN110714057A (zh) | 2018-07-11 | 2020-01-21 | 成都金洛克生物技术有限公司 | 用于检测外源基因整合和定位的通用型fish探针及其应用 |
| CN109504709B (zh) | 2018-11-28 | 2020-07-24 | 上海安民生物技术有限公司 | 白蛋白启动子驱动的白蛋白表达载体 |
| WO2020172659A1 (en) | 2019-02-22 | 2020-08-27 | Smith & Nephew, Inc. | Combination electrosurgical and mechanical resection device |
| CA3137457A1 (en) | 2019-05-07 | 2020-11-12 | Amgen Inc. | Vectors and expression systems for producing recombinant proteins |
-
2018
- 2018-05-24 KR KR1020197038087A patent/KR20200018488A/ko not_active Ceased
- 2018-05-24 JP JP2020515296A patent/JP2020520677A/ja active Pending
- 2018-05-24 CN CN201880049768.4A patent/CN111093641A/zh active Pending
- 2018-05-24 KR KR1020257020185A patent/KR20250093434A/ko active Pending
- 2018-05-24 BR BR112019024750-5A patent/BR112019024750A2/pt active Search and Examination
- 2018-05-24 WO PCT/GB2018/051415 patent/WO2018215780A1/en not_active Ceased
- 2018-05-24 EP EP22176864.1A patent/EP4119133A1/en active Pending
- 2018-05-24 IL IL270817A patent/IL270817B2/en unknown
- 2018-05-24 AU AU2018272294A patent/AU2018272294B2/en active Active
- 2018-05-24 CA CA3064352A patent/CA3064352A1/en active Pending
- 2018-05-24 CN CN202410244176.5A patent/CN118105471A/zh active Pending
- 2018-05-24 US US16/616,884 patent/US12359184B2/en active Active
- 2018-05-24 EP EP18728717.2A patent/EP3630077A1/en active Pending
- 2018-05-24 EP EP23206416.2A patent/EP4295904A3/en active Pending
- 2018-05-24 MX MX2019014027A patent/MX2019014027A/es unknown
-
2019
- 2019-11-22 MX MX2024002249A patent/MX2024002249A/es unknown
-
2022
- 2022-06-03 US US17/832,564 patent/US12338471B2/en active Active
- 2022-06-03 US US17/832,562 patent/US11932885B2/en active Active
-
2023
- 2023-03-10 JP JP2023038030A patent/JP7688926B2/ja active Active
- 2023-10-30 US US18/497,740 patent/US20240150746A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201089A patent/AU2024201089B2/en active Active
- 2024-02-26 JP JP2024026784A patent/JP2024059833A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12234300B2 (en) | Conjugated hepcidin mimetics | |
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| JP6525471B2 (ja) | ヘプシジン類似体及びその使用 | |
| CN102917726B (zh) | 干扰素类似物 | |
| JP2018522563A5 (enExample) | ||
| AU781678C (en) | Compositions and methods for counteracting effects of reactive oxygen species and free radicals | |
| JP2010518079A5 (enExample) | ||
| JP2017523959A (ja) | ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 | |
| JP2012529296A5 (enExample) | ||
| TW201819398A (zh) | 治療性肽 | |
| RU2012106150A (ru) | Вариантные формы уратоксидазы и их применение | |
| HRP20191852T1 (hr) | Polipeptidi | |
| JP2013504589A5 (enExample) | ||
| CN110891612A (zh) | 蛋白质药物与p/a肽的缀合物 | |
| JP2024520861A (ja) | 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 | |
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| JP2014506450A5 (enExample) | ||
| HRP20201081T1 (hr) | Inhibitorni peptidi porijeklom od trem-sličnog transkripta 1 (tlt-1) i njihove uporabe | |
| US20230158100A1 (en) | Treatment of panx1 associates diseases | |
| JP2013529178A5 (enExample) | ||
| AU2021401137B2 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| WO2012104462A1 (es) | Heptapéptidos y su uso para el control de la hipertensión | |
| CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| CN108350033A (zh) | 端粒酶易位的肽抑制剂及其治疗用途 | |
| JP2012510518A (ja) | 体液貯留障害を処置するための方法および組成物 |